Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Reviva Pharmaceuticals Hldg Inc (RVPH)

Reviva Pharmaceuticals Hldg Inc (RVPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
10 Stocks Retailers Are Most Bullish/Bearish About On Tuesday

Earnings have largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.

ALDX : 4.76 (-13.39%)
STIM : 0.6900 (-37.27%)
PGY : 10.88 (-35.58%)
QSI : 0.7753 (-22.43%)
MNOV : 2.2800 (+49.02%)
AXSM : 99.49 (+9.35%)
VSAT : 8.41 (-6.56%)
ZS : 209.04 (+4.76%)
BTM : 2.51 (-6.34%)
RVPH : 1.3200 (+32.00%)
SPY : 596.90 (-0.31%)
XBI : 100.51 (-2.92%)
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

RVPH : 1.3200 (+32.00%)
Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

RVPH : 1.3200 (+32.00%)
Reviva to Participate in the UBS Global Healthcare Conference

RVPH : 1.3200 (+32.00%)
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

RVPH : 1.3200 (+32.00%)
Reviva Pharmaceuticals Provides Update on Clinical Development Pipeline

Enrollment remains on pace for Reviva’s Phase 3 clinical trial for the treatment of schizophrenia at 15 sites across the US with enrollment set to begin at...

RVPH : 1.3200 (+32.00%)
Reviva Pharmaceuticals to Participate in the 2022 BIO International Convention

CUPERTINO, Calif.,, June 02, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...

RVPH : 1.3200 (+32.00%)
Reviva Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

CUPERTINO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...

RVPH : 1.3200 (+32.00%)
Reviva Pharmaceuticals Holdings, Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights

- Hosted key opinion leader (KOL) webinar on brilaroxazine for schizophrenia and other neuropsychiatric disorders led by industry thought leaders Leslie...

RVPH : 1.3200 (+32.00%)
Reviva Pharmaceuticals Announces Update on RECOVER, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for the Treatment of Schizophrenia

CUPERTINO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage...

RVPH : 1.3200 (+32.00%)

Barchart Exclusives

1 Dividend Aristocrat to Bet on Trump's Tariffs and the Fed's Rate Cuts
Nucor is one stock that stands to benefit from the Fed's rate cuts as well as any possible tariffs under a Trump administration. It is also a dividend aristocrat, and has increased its payouts for over 5 decades. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar